hpg1860

HPG1860 is a structurally novel, orally administered, non-bile acid small molecule that acts as a potent, selective, and full agonist of the farnesoid X receptor (FXR). FXR is a ligand-activated nuclear receptor that regulates genes involved in bile acid metabolism, inflammation, fibrosis, and lipid/glucose homeostasis. By activating FXR, HPG1860 aims to reduce liver fat content and modulate disease processes relevant to non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Preclinical studies demonstrated high selectivity for FXR with favorable pharmacokinetics and safety profiles. In clinical trials—including Phase I in healthy volunteers and ongoing Phase IIa studies in NASH patients—HPG1860 has shown robust target engagement through C4 reduction and FGF19 activation without significant adverse events such as pruritus or LDL elevation. The drug is being developed by Hepagene Therapeutics[1][3][4][5][6][7].